Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
about
Plasminogen activator inhibitor type-1 and interleukin-6 in haemolytic uraemic syndrome.New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison.Shiga toxin pathogenesis: kidney complications and renal failure.Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot LysisChemotherapy-induced hemolytic uremic syndrome: description of a potential animal model.Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria.Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium.Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation.Plasminogen activator inhibitor-1 and the kidney.Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosisEffects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
P2860
Q33333545-DC81A98C-BF72-41AE-B546-9581A2512A1BQ33339749-59424F00-2E00-4EB8-A8DE-A9BC01836933Q33379319-AA6AE5B2-B2B9-4AD3-9ADF-C48EB8C924ECQ33397541-54C344B0-99D7-4D3A-AD07-EEB6B3B3D5C8Q33406356-A257F172-35CE-4B83-BE11-73EB94EAA75DQ33410276-69F32DFF-6135-454D-85CC-CBF46FC77167Q33430429-3158B146-E9A5-4D73-8849-4C15176AB162Q33495566-F9E650A4-8364-4BC4-BE2A-A03796C60EEDQ33497554-1388975D-810B-465C-86E3-2DE325808C4CQ33501391-33A4CA0E-71B4-46D4-9243-6D196368BEBEQ33503498-8AEB3CDC-EB6E-4A44-8A28-7575614EE54FQ33960082-6C3FFF6E-B2A3-4E60-AE3D-DBCBFA3C36ABQ35178613-8DBB20E2-7047-4391-BA76-0DF0BFFE94C3Q35763454-10B33D16-66F2-4420-8F97-0ED2469DE4B3Q46417157-4C1775A9-5C54-4012-B16A-7BC74E04491A
P2860
Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@ast
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@en
type
label
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@ast
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@en
prefLabel
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@ast
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@en
P2093
P1476
Role of plasminogen-activator ...... the hemolytic uremic syndrome.
@en
P2093
P304
P356
10.1056/NEJM199209103271102
P407
P577
1992-09-01T00:00:00Z